Company: BDRX
Filing Date: 2025-11-17
Form Type: F-1
Source: 0001214659-25-016821
Chunk: 49

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-11-17
Form: F-1
Chunk 49
---
wang Amendment,
Melior and Bukwang entered into a royalty agreement pursuant to which Bukwang shall be entitled to 50% of all payments Melior receives
under the License Agreement, including: (i) 50% of the equity issued by us under the License Agreement, and (ii) 50% of the royalties
that we will pay to Melior. Further, under the royalty agreement, Bukwang will pay to Melior $100,000 in consideration for Melior’s
waiver of Bukwang’s obligation to pay patent costs pursuant to the Bukwang License, and Melior will take back responsibility for
all tolimidone patent prosecution and maintenance costs.

Additional Information

Additional information regarding the Company, including
our intellectual property, sales and marketing, research and development capabilities, competitors and regulatory environment, is set
forth in our Annual Report on Form 20-F for the year ended December 31, 2024 and the other documents we incorporate by reference herein.

| 31 |

<div align='center'>PRINCIPAL SHAREHOLDERS</div>

The following table sets forth information, to our knowledge,
as of November 1, 2025, regarding the beneficial ownership of Ordinary Shares (including those represented by Depositary Shares), including:

| · | each person, or group of affiliated persons, that is known by us to be a beneficial owner of 5% or more   
 of Ordinary Shares (based on information in our share register and information provided by such persons); |

| · | each member of our Board of Directors; |

| · | each member of our senior management; and |

| · | all members of our Board of Directors and our senior management, taken as a group. |

Beneficial ownership of shares is determined
under rules of the SEC and generally includes any shares over which a person exercises sole or shared voting or investment power. Except
as noted by footnote, and subject to community property laws where applicable, we believe, based upon the information provided to us,
that the persons and entities named in the table below have sole voting and investment power with respect to all Ordinary Shares shown
as beneficially owned by them. The percentage of beneficial ownership is based upon 61,952,308,922 Ordinary Shares outstanding as of November
1, 2025. Ordinary Shares subject to options or warrants currently exercisable or exercisable within 60 days of November 1, 2025 are deemed
to be outstanding and beneficially owned by the person holding the options